Biotech

BioInnovation Institute Receives a Grant from the Gates Foundation to Launch a New Initiative Focused on Women’s Health

BioInnovation Institute (BII), a non-for profit Foundation known for incubating and advancing world-class life science research, has received a grant from the Bill & Melinda Gates Foundation to accelerate efforts to discover translational world-class research to identify new technologies and solutions that can improve the health of women and girls across the world, including low-income countries.  The grant supports BII’s vision to strengthen the…

Gameto Raises $23M to Redefine Reproductive Longevity with Reprogrammed Ovarian Cells

Gameto, a biotechnology startup solving the problem of accelerated ovarian aging to change the trajectory of women’s health and equality, today announced that it has raised a $20M in Series A funding led by Future Ventures, with participation from Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures, Overwater Ventures, Robert Nelsen and Anne Wojcicki. Gameto also raised $3M in Seed funding in March 2020 from a range of notable investors…

New Study: Mirvie Can Predict Pregnancy Complications Months Before They Happen

Mirvie, a pioneer in predicting unexpected pregnancy complications, has announced the publication of a study in Nature proving the proprietary Mirvie RNA platform is first to predict unexpected complications by revealing the underlying biology of each pregnancy. The research analyzed the largest and most diverse dataset of maternal transcriptomes to date. The platform opens a new window into pregnancy health for women to act…

Women’s Health Biotech Company ObsEva Is Added to the NASDAQ Biotechnology Index

ObsEva has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The biotech company develops and commercializes novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment…

Will Brown Is ObsEva’s New Chief Financial Officer

ObsEva, a biotech company focused on women’s reproductive health has appointed Will Brown as Chief Financial Officer and member of the company’s Executive Committee, effective January 1, 2022. Will Brown is a Certified Public Accountant with deep experience in capital markets, accounting, and finance. Mr. Brown joins ObsEva from Altimmune, Inc. (NASDAQ: ALT) where he served as Chief Financial Officer and was…

Schrödinger Receives a $4.9M Grant from the Gates Foundation to Accelerate Drug Discovery in Women’s Health

Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, has been awarded a two-year, $4.9M grant from the Bill & Melinda Gates Foundation to support a global women’s health initiative. The grant is part of a Gates Foundation initiative aimed at accelerating emerging opportunities to advance the field of contraceptive drug discovery. The emphasis of this initiative…

Helaina Raises a $20M Series A to Scale Production of its Human Breast Milk Proteins Using Precision Fermentation

Helaina, a company using precision fermentation to recreate immune-equivalent proteins previously only available in breast milk, has raised $20M in Series A funding co-led by Spark Capital and Siam Capital with participation from Primary Venture Partners, Plum Alley Investments, Tom Williams, Hannah Bronfman, Gabrielle Union, Matt Rutler and Barrel Ventures, among other strategic partners. The company was founded in 2019 by by food scientist and entrepreneur Laura Katz, who aspired…

Organon Announces Plans to Acquire Forendo Pharma, a Biotech Company Targeting Endometriosis and PCOS

Organon and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1)…